RajeshPahwaMD

Neurology • Kansas City, KS

Movement Disorder

Professor, Neurology, University Kansas School of Medicine

Join to view full profile

Dr. Pahwa is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Pahwa's full profile

Already have an account?

Office
3599 Rainbow Blvd
Kansas City, KS 66160
Phone+1 913-588-6970

Fax+1 913-535-2103

Summary

Dr. Rajesh Pahwa is a neurologist in Kansas City, KS and is affiliated with The University of Kansas Health System. He received his medical degree from Seth G.S. Medical College and has been in practice 34 years. He specializes in movement disorder and is experienced in parkinson's disease, deep brain stimulation and clinical trials.

Education & Training

University of Kansas School of MedicineResidency, Neurology, 1991 - 1992
Baylor College of MedicineResidency, Neurology, 1987 - 1991
Seth G.S. Medical CollegeClass of 1983

Certifications & Licensure

MO State Medical License 2021 - 2026
KS State Medical License 1991 - 2025
American Board of Psychiatry and Neurology Neurology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com

Clinical Trials

Pramipexole Conversion to Ropinirole Controlled Release (CR) Start of enrollment: 2006 Jan 01
Completed
Phase 3
Efficacy of Orally Disintegrating Selegiline in Parkinson's Patients Experiencing Adverse Effects With Dopamine Agonists Start of enrollment: 2007 Mar 01
Completed
Phase 4
A Pilot Study of Oxaloacetate in Subjects With Treated PD Start of enrollment: 2012 Dec 01
Completed
Phase 2, Phase 3
Retrospective, Non-significant Risk, Deep Brain Stimulation (DBS) Care Management Software Feasibility Study Start of enrollment: 2012 Nov 01
Completed
Connect.Parkinson: Connecting Individuals With Parkinson Disease to Specialists in Their Homes Start of enrollment: 2014 Mar 01
Completed
Not Applicable
Evaluation of Safety and Tolerability of ENT-01 for the Treatment of Parkinson's Disease Related Constipation Start of enrollment: 2017 May 11
Completed
Phase 1, Phase 2
Evaluation of the Personal KinetiGraph™ (PKG™) to Improve Insight Into Parkinson's Disease Status Start of enrollment: 2017 May 17
Active, not recruiting
Not Applicable
Fixed-Dose Trial in Early Parkinson's Disease (PD) Start of enrollment: 2019 Dec 13
COMPLETED
PHASE3
Roles: Contact
Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3) Start of enrollment: 2020 Sep 23
COMPLETED
PHASE3
Roles: Contact
A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004 Start of enrollment: 2016 Jul 01
Unknown status
Phase 3
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Management of Parkinson's disease psychosis: first-line antipsychotic selection and rationale for continuing, combining, or switching.
Stuart H Isaacson, Henry Nasrallah, Rajesh Pahwa, Gustavo Alva, Daniel Kremens
Expert Opinion on Pharmacotherapy. 2025-03-27
Continuous, subcutaneous apomorphine infusion for Parkinson disease motor fluctuations: Results from the phase 3, long-term, open-label United States InfusON study.
Stuart H Isaacson, Alberto J Espay, Rajesh Pahwa, Pinky Agarwal, Holly A Shill
Journal of Parkinson's Disease. 2025-01-29
A Pilot Study of AI-Controlled Transcutaneous Peripheral Nerve Stimulation for Essential Tremor.
Richard Dewey 3rd, Stuart Isaacson, Richard Dewey Jr, Sagari Betté, Kelly E Lyons
Tremor and Other Hyperkinetic Movements. 2025-01-01

Press Mentions

Supernus Announces FDA Approval of ONAPGO™ (Apomorphine Hydrochloride) for Parkinson’s DiseaseFebruary 4th, 2025
Wren Builds Out Scientific Advisory Board for Neurodegenerative DiseasesJanuary 4th, 2023
Dosing Begins in Phase 1 Trial of AP-472, for Dyskinesia with LevodopaOctober 7th, 2021
Join now to see all